Maxim Group analyst Naz Rahman maintained a Buy rating on NexGel Inc (NXGL – Research Report) yesterday and set a price target of $5.00. The company’s shares opened today at $1.52.
Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, Viking Therapeutics, and 9 Meters Biopharma. According to TipRanks, Rahman has an average return of -38.6% and a 13.04% success rate on recommended stocks.
NexGel Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See the top stocks recommended by analysts >>
Based on NexGel Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $561 thousand and a GAAP net loss of $1.04 million. In comparison, last year the company earned a revenue of $417 thousand and had a GAAP net loss of $826 thousand
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NXGL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NexGel Inc is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics.
Read More on NXGL:
- NEXGEL to Participate in Upcoming Investor Conferences in October 2022
- SAGE Journals Publishes New Data Revealing NEXGEL’s SilverSeal Hydrogel Dressing Improves Postsurgical Scarring
- NexGel announces new dat a on SilverSeal published in SAGE journal
- NexGel appoints Nelson, Chesen to scientific advisory board
- NEXGEL Appoints Dr. Leonard Nelson and Dr. Neil Chesen to Scientific Advisory Board
